Mathematical Modeling Identifies Aggressive Prostate Cancer That Needs Treatment

Mathematical Modeling Identifies Aggressive Prostate Cancer That Needs Treatment

A new approach to mathematical modeling of prostate cancer has made it possible to spot potentially life-threatening tumors among the ones that are less threatening, allowing physicians to selectively offer aggressive treatment to those in need.

The findings, published in the journal European Urology Focus, may help reduce the severe side effects of cancer treatment among men whose cancers do not yet need to be treated.

“Curative treatment of early prostate cancer by surgery or radiotherapy needs to ideally be targeted to the minority of men with significant cancers, so that the remainder are spared the side effects of treatment, which frequently includes impotence,” Colin Cooper, a professor of cancer genetics at UEA’s Norwich Medical School, said in a press release.

Discriminating between aggressive and more benign tumors in prostate cancer has been challenging because of the range of variability seen when examining thes tumors under a microscope.

Earlier attempts to use mathematical modeling to classify prostate cancer have failed. This time researchers at the University of East Anglia used a method called Latent Process Decomposition (LPD). This computational technique assesses the structure of a data set, without making use of clinical outcomes information.

Using this approach, researchers studied gene activity in prostate cancer samples This allowed them to identify a pattern found only in tumors likely to have severe health consequences. The research team named these cancers DESNT.

“These were categorized by low expression of a core set of 45 genes, many encoding proteins involved in the structure of cells, transport of ions and cell adhesion,” said Vincent Moulton, a professor at UEA’s School of Computing Sciences. “This was common across the samples of cancers known to have a poor patient prognosis.”

“We urgently need to be able to tell the difference between aggressive prostate cancers that could go on to kill and those that won’t,” said Dr. Iain Frame, director of research at Prostate Cancer U.K.

“Cracking this problem remains one of the biggest challenges in tackling the disease. Currently, too many men receive treatments and endure life-changing side effects for cancers that may never cause them harm. This is why Prostate Cancer UK is investing heavily in research to find better diagnostic tests that will transform diagnosis within the next ten years,” Frame added.

He said the research findings are also important since they add key information about the mechanisms that make a prostate cancer aggressive. Such knowledge will help provide earlier and more accurate diagnoses, in addition to informing physicians on the best treatment options, he said.

“The existence of this distinction is a significant step in assisting in the targeting of appropriate therapy, and helping to avoid overtreatment,” Cooper said.